Acorda Jumps as Parkinson???s Drug Performs Well in Late-Stage Study

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks5.jpg" NAME"Acorda Jumps as Parkinsons Drug Performs Well in Late-Stage Study" ALT"Acorda Jumps as Parkinsons Drug Performs Well in Late-Stage Study"June 6, 2017By Alex Keown, BioSpace.com Breaking News Staff<BR...…

Continue ReadingAcorda Jumps as Parkinson???s Drug Performs Well in Late-Stage Study

Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up

  • Post author:
  • Post category:BioPharma

  Life Sciences Jobs   ... Source: BioSpace

Continue ReadingJanssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up

New Immuno-Onco Deal With Merck KGaA Could Make This UK Biotech a $1 Billion Company

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-deal3.jpg" NAME"New Immuno-Onco Deal With Merck KGaA Could Make This UK Biotech a $1 Billion Company" ALT"New Immuno-Onco Deal With Merck KGaA Could Make This UK Biotech a $1…

Continue ReadingNew Immuno-Onco Deal With Merck KGaA Could Make This UK Biotech a $1 Billion Company